Probiotics, radiation, chemo, and immunotherapy for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if adding probiotics (good bacteria) to standard chemoradiation and an immunotherapy drug (adebrelimab) can help treat limited-stage small cell lung cancer. It may improve how well the treatment works and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with small cell lung cancer that has not spread beyond one side of the chest (limited stage).
- You are between 18 and 80 years old.
- You are able to care for yourself and are up and about (ECOG performance status 0 or 1).
- You have had no more than 2 rounds of chemotherapy or chemotherapy plus immunotherapy before joining.
- You have not received chest radiation therapy in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery, followed by surgery and radiation, is effective for limited-stage small cell lung cancer. The goal is to see if this approach helps control the cancer better than standard treatment alone.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
This trial looks at whether giving additional targeted radiation to the chest can help people with extensive-stage small cell lung cancer after they finish standard chemo-immunotherapy. It may help control the cancer in the lung area and prevent it from coming back there.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.